Bank of New York Mellon Corp purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 36,913 shares of the company’s stock, valued at approximately $607,000. Bank of New York Mellon Corp owned about 0.07% of Upstream Bio as of its most recent SEC filing.
Separately, Moody Aldrich Partners LLC acquired a new position in Upstream Bio in the fourth quarter worth $1,229,000.
Upstream Bio Price Performance
Shares of NASDAQ:UPB opened at $6.84 on Thursday. The firm has a fifty day simple moving average of $8.79. Upstream Bio, Inc. has a twelve month low of $6.64 and a twelve month high of $29.46.
Upstream Bio Company Profile
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Upstream Bio
- What Are Dividend Champions? How to Invest in the Champions
- Energy Transfer: Powering Data With Dividends and Diversification
- Differences Between Momentum Investing and Long Term Investing
- Qualcomm Stock Is Coiling for a Breakout
- How to Plot Fibonacci Price Inflection Levels
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
